COMMUNIQUÉS West-GlobeNewswire

Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
12/05/2026
Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cells Correlation established between EO2463-induced and B cell target-specific CD8 T- [...]
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
12/05/2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to present results from Phase IIa trial for first-in-class anti-virulence therapy [...]
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
12/05/2026
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial 1 Participants treated with the [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]
Rapid Nutrition Extends AI-Powered Agentic Platform to Consumer Ecosystem Following Investor Rollout
12/05/2026
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, today announced the [...]
Q1 2026 Update: Tecan on track with low-single-digit local currency growth in Q1; full-year 2026 outlook confirmed
12/05/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q1 2026 Update: Tecan on track with low-single-digit local currency growth in Q1; full-year 2026 outlook confirmed Männedorf, [...]
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
12/05/2026
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single ‑ assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
12/05/2026
May 12, 2026 News release BioPorto A/S to h ost an investor webcast on the results for the first quarter of 202 6 COPENHAGEN, DENMARK, May 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR [...]
Enlitic’s Ensight Goes Live at RHCNZ, Advancing Radiology Workflow Efficiency in New Zealand
12/05/2026
LOVELAND, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Enlitic, a global leader in radiology and imaging data, today announced the successful go-live of its Ensight platform at RHCNZ Medical Imaging Group (RHCNZ), New [...]
Gala Health GLP-1 Compounded and Branded Weight Loss Medication Options with Real Doctor Support
12/05/2026
How Gala GLP-1 Compounded Semaglutide, Tirzepatide, and Microdosing Options Work for Prescription Weight Management Without Insurance in 2026 Wilmington, Delaware, May 11, 2026 (GLOBE NEWSWIRE) -- Compounded medications [...]
Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies
12/05/2026
Partnership combines venture creation and biologics discovery to accelerate novel medicines through human clinical proof of concept First-of-its-kind collaboration between a specialist biotech venture firm and a [...]
FDA Advances Drug Repurposing to Address Unmet Medical Needs
11/05/2026
Agency is particularly focused on new uses to treat chronic or rare diseases White Oak, Md., May 11, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced it is soliciting input on efforts with [...]
Ceribell Reports First Quarter 2026 Financial Results
11/05/2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026
11/05/2026
NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company, today announced that the Company will release its first quarter operating results on [...]
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
11/05/2026
- First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented - - Visit CG Oncology at booth #3051 - DALLAS, May [...]
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/05/2026
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs [...]
Oculis Reports Q1 2026 Financial Results and Provides Company Update
11/05/2026
Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, [...]
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
– LOQTORZI ® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug [...]

Pages